Amgen
Biotech company creating biologic medicines
Manager, Membership - Contracts & Pricing Execution, AIN
About the job
- A Master's degree in business administration, Finance, Commerce, Economics, Life Sciences, Pharmacy, Healthcare Administration, or a related field.
- 8 to 12 years of experience in pharmaceutical commercial operations, Membership operations, Market Access, Customer Master Data, Managed Markets, Contracts & Pricing, Revenue Management, or related business functions.
- At least 2 years of people leadership, project leadership, or process ownership experience.
- Strong analytical, operational, stakeholder management, and problem-solving skills.
- Experience working in regulated environments with controls, governance, and compliance requirements.
- Lead end-to-end Membership operations, including customer onboarding, eligibility validation, customer setup, system alignment, ongoing maintenance, reporting, and closeout activities.
- Ensure execution within established service-level agreements, quality standards, operational controls, and compliance requirements.
- Oversee intake and triage for membership requests, declaration forms, roster updates, customer changes, and contract alignment activities.
- Serve as the primary escalation point for issues affecting customer eligibility, membership alignment, customer setup, and stakeholder satisfaction.
- Lead governance of customer eligibility determinations, GPO participation validation, class-of-trade assessments, contract alignment reviews, and membership approvals.
- Oversee validation involving DEA, HIN, HIBCC, HRSA, OneKey, customer identifiers, legal entity hierarchies, and parent-child relationships.
- Review and approve complex customer setup requests, hierarchy modifications, contract eligibility decisions, and compliance-sensitive customer updates.
- Govern customer additions, drops, strategy changes, acquisitions, organizational restructures, and customer maintenance requests.
- Oversee customer setup and maintenance across HCM, GCPS, SAP, MDM, OneKey, and related commercial operations platforms.
- Ensure timely creation and maintenance of customer records, legal entity hierarchies, customer attributes, contract affiliations, and GPO alignments.
- Partner with MDM and Information Systems teams to resolve customer data issues, interface failures, hierarchy challenges, and system synchronization problems.
- Support user acceptance testing, system enhancements, process automation initiatives, and technology transformation efforts.
- Lead customer eligibility dispute investigations, denial reviews, rebuttal activities, and exception resolution processes.
- Provide decision support and recommendations for disputed customer eligibility determinations involving GPOs, wholesalers, and internal stakeholders.
- Ensure documentation, audit trails, business rationale, and stakeholder communications support membership decisions.
- Drive resolution of complex operational issues affecting pricing access, membership alignments, customer eligibility, rebates, chargebacks, and contract execution.
- Oversee quarterly Public Health Service and 340B eligibility maintenance activities, including OPA file reviews, customer additions, removals, and eligibility updates.
- Ensure timely maintenance of SAP flags, CPOCOT assignments, customer eligibility statuses, and contract alignments supporting 340B participation.
- Govern controls supporting wholesaler notifications, eligibility reporting, and system synchronization activities.
- Provide oversight for VA, Kaiser, OBU, IBU, Specialty Pharmacy, Hospital Coalition, and other specialized Membership programs.
- Own Membership KPI reporting, service-level agreement reporting, operational dashboards, management reporting, customer eligibility reporting, and ad hoc analytical requests.
- Lead trend analysis, root cause investigations, workload assessments, dispute reviews, and operational health monitoring.
- Identify and implement process improvements, automation opportunities, reporting enhancements, and productivity initiatives.
- Support special projects, business initiatives, system implementations, and transformation efforts.
- Maintain audit-ready documentation supporting customer eligibility determinations, approvals, setup activities, roster updates, and membership decisions.
- Support SOX testing, internal audits, compliance reviews, and control monitoring activities.
- Identify and mitigate operational, financial, compliance, and data quality risks.
- Lead, coach, and develop Membership Associates and Senior Associates within AIN.
- Establish performance expectations, quality standards, career development plans, and capability development frameworks.
- Support hiring, onboarding, knowledge transfer, and workforce planning activities.
- Partner with ATO subject-matter experts to establish standard operating procedures, training plans, readiness criteria, governance models, and transition plans for migrating Membership activities into AIN.
- Deep understanding of U.S. pharmaceutical customer eligibility, GPO operations, customer master data management, Market Access, and Membership governance.
- Experience with GCPS, HCM, SAP, Model N, OneKey, HIBCC, HRSA/OPA, Tableau, Power BI, and related commercial operations systems.
- Knowledge of 340B, Public Health Service, Hospital Coalition, Specialty Pharmacy, VA, Kaiser, OBU, IBU, customer onboarding, and eligibility processes.
- Experience with Model N GCPS, SAP, Conga, IntegriChain, Tableau, Qlik, Power BI, Power Query, Alteryx, SharePoint, and automation technologies.
- Experience supporting audits, SOX controls, governance programs, and operational transformation initiatives.
- Experience leading global delivery teams, transition programs, and capability-building initiatives.
- Strong leadership, executive communication, stakeholder management, and change-management skills.
About the company
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
- Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
- MariTide now has nine ongoing and three planned Phase 3 studies across obesity.
What critics are saying
- Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
- FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
- If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.
What makes Amgen unique
- Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
- IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
- Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.
Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.
Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.
Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.
Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.